Guidelines on the investigation and management of antiphospholipid syndrome (Q37982121)

26 August 2017

title

Guidelines on the investigation and management of antiphospholipid syndrome (English)

1 reference

British Committee for Standards in Haematology

26 August 2017

author

object named as

British Committee for Standards in Haematology

1 reference

26 August 2017

David Keeling

1 reference

26 August 2017

Ian Mackie

1 reference

26 August 2017

Gary W Moore

1 reference

26 August 2017

Ian A Greer

1 reference

26 August 2017

Michael Greaves

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

British Journal of Haematology

26 August 2017

published in

1 reference

26 August 2017

volume

157

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

47-58

1 reference

Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid antibodies in women at risk for preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Guidelines for point-of-care testing: haematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

A critical assessment of the role of antiphospholipid antibodies in infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Migraineurs show a high prevalence of antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

β(2) -Glycoprotein I: evolution, structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Conceptions and misconceptions in testing for lupus anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

How I treat the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Current concepts on the pathogenesis of the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

How we diagnose the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Seronegative antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Management of antiphospholipid antibody syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

The potential role of heparin in assisted conception

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Point-of-care testing in haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Technical aspects in laboratory testing for antiphospholipid antibodies: is standardization an impossible dream?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid syndrome: an evolving story

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

The role of complement in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09037.X

10.1111/J.1365-2141.2012.09037.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference